Health

  • |

    The Miracle Arrives With a $3.2 Million Invoice

    ByPhil McCracken

    Here is the money trail presented by the scenario: children’s-hospital and academic micro-dystrophin research tied to Nationwide Children’s Hospital moves into Sarepta’s private commercialization pipeline, and the number waiting at the end is $3.2 million. Nationwide is presented as receiving licensing and royalty revenue; families and payers are presented as facing the cost. That is a remarkable invoice-routing system: the science gets described as a shared triumph, while the people who need it are treated like they wandered into the pricing meeting without a badge.

    Profit is not the villain. Pretending the public-private pipeline ends at “innovation” is. If the figure and licensing arrangement are accurate as presented, the contradiction is hard to miss: the breakthrough gets inspirational music, the commercial deal gets revenue, and the family gets a financial document written in the ancient language of “please indicate which organ you’d like to sell first.” Nobody has to oppose useful medicine or licensing to ask why the people carrying the medical and financial risk get no meaningful seat at the pricing table.

  • |

    Medicare’s Taxpayer-Funded Layaway Plan

    ByHarlan Quill

    At the courthouse-basement level of policy math, the arrangement is hard to defend: taxpayers help absorb the early risk of medical discovery, then a private patent can put the finished medicine behind a padlock while Medicare and patients meet the checkout price.

    That is a taxpayer-funded layaway plan. We help finance the scientific groundwork, a company controls the bottle, and the public returns to retrieve its medicine with a bill wearing a shareholder-return hat. If public support helps make a breakthrough possible, public policy should at least ask what public value comes back. Otherwise, we did not merely buy the breakthrough; we rented it back from the company that put a padlock on the bottle.

  • |

    Medicare Paid More Than the Bill, Because Apparently Even the Bill Needs Oversight

    ByHugh Jass

    I have spent the morning exhuming a HHS-OIG audit, and the document coughed. The review examined 801 selected Medicare Part B claim lines from payments made in 2022 and 2023. Among them were 138 incorrect lines that produced at least $140,182 in overpayments. Another 31 lines, totaling $76,640, lacked supporting documentation. This is not proof that every claim was improper; it is a selected sample with enough administrative thunder to make the filing cabinet nervous.

    The target here is not patients or an accusation that providers acted intentionally. The target is the payment-control machinery: the edits, reviews, and safeguards assigned to notice when Medicare money is headed somewhere it should not go. Wisconsin Physicians Service Insurance Corporation already had system edits and follow-up procedures intended to identify overpayments. HHS-OIG still found incorrect payments and unsupported claim lines in the reviewed sample, which suggests the controls were present in the same way a smoke detector is present during a very organized kitchen fire.

    Hugh Jass Serious Investigative Reporting has located the central contradiction: the claim was important enough to generate edits, reviews, and recommendations, but not important enough to stop the money first. The system had a process for checking the paperwork, a process for checking the checking, and apparently a later process for discovering that the first two processes had allowed the money to leave the building wearing sunglasses.

    HHS-OIG recommended corrective action, and WPS concurred with those recommendations. The audit does not establish a recovery outcome, so the responsible sentence ends there. That restraint is called evidence, a rare substance often found in the same room as a spreadsheet but never invited to the budget meeting.

    The invoice, in other words, survived quality control by becoming a payment. Before the money moved, the bill was suspicious. After the money moved, it appears to have received diplomatic immunity. Medicare oversight is supposed to catch mistakes; in this case, the auditors had to audit the audit trail, proving once again that paperwork is not useless. It is merely waiting for another layer of paperwork to explain why it failed.

  • |

    If Prices Can Fall Now, Who Approved the Old Ones?

    ByHarlan Quill

    I have spent enough time with budgets to know that when a Medicare drug price falls after negotiation, the old price deserves an audit—not a standing ovation. The usual sales pitch says Medicare must accept whatever number arrives in the envelope, as though drug pricing were a weather event and not a market with lawyers. Then bargaining happens, the bill gets smaller, and “impossible” suddenly develops a discount code.

    The exact before-and-after figures may be illustrative, and lower prices do not automatically shrink every patient’s copay. But the practical point survives the fine print: negotiation can reduce public spending and may ease the bill at the pharmacy counter. The people defending the old system now have to explain why savings were forbidden until someone asked for them. The national drug-pricing spreadsheet has ruled that “unavoidable” was apparently the premium tier, complete with a lobbyist and no cancellation button.

  • |

    A Capitol Fourth Learned That the Sun Has a Security Policy

    ByAmanda Lynn

    I love a patriotic chorus, but at this year’s Capitol Fourth, the most powerful event official was not the producer, the branding department, or the person holding the ticket. It was the sun, arriving with temperatures exceeding 100 degrees and immediately rewriting the run of show. The U.S. Capitol Police restricted rehearsal, delayed public gates until 7 p.m., and kept the concert scheduled for 8 p.m. The weather had better stage management than half the festival circuit.

    That guidance matters because a ticket buys access to an event; it does not enlist a fan in a heat endurance competition. Organizers told guests they could bring water containers, which is helpful, because apparently hydration must now pass through the same security theater as a suspiciously large belt buckle. The ordinary concertgoer is left to calculate the patriotic experience: stand outside, navigate the gates, manage the heat, and hope the evening behaves—or watch from home, as police advised people at higher risk to consider doing.

    There is the contradiction: safety is treated as essential enough to delay entry and restrict rehearsal, but optional enough to sound like a personal lifestyle choice. “You may want to watch from home” is a very polite way of saying the safest seat might be the couch, where nobody asks you to prove your love of fireworks by sweating through your shirt.

    This is not an argument against public concerts or national celebrations. It is an argument against turning attendance into a loyalty test. Fans are workers, parents, older people, disabled people, and regular humans with bodies that do not become weatherproof because a sponsor placed a flag near the stage. The show matters; so does whether getting there asks people to gamble with their health.

    So congratulations to the sun, the evening’s unbooked headliner: security chief, schedule editor, hydration consultant, and streaming-sales representative. It was the only authority willing to say, “Please enjoy responsibly from your couch.”

    Sources

  • |

    Skysona and the $3 Million Toll Booth

    ByPhil McCracken

    I audit public-private invoices for a living, and Skysona arrives looking like a federal infrastructure project with a very expensive toll booth. The premise is straightforward: NIH support, academic medical centers, and basic research helped build the gene-therapy road, while bluebird bio brought a finished treatment to market with a $3 million price tag. Rare-disease therapies are complex, and private development matters. Fine. Complexity is not a magic eraser for the public role.

    The money trail deserves more than an innovation ribbon-cutting. If taxpayers and public institutions carried part of the long, uncertain research burden, patients and families are entitled to ask what public return comes with the private invoice. Nobody is claiming bluebird bio did nothing; the question is who absorbed the early risk and who gets the reward when science becomes a product. Taxpayers helped pave the road. Calling the toll booth innovation does not make the receipt disappear.

  • |

    AdaptHealth’s “Password File” Got Exfiltrated, So Now Everyone Pays the Bill Twice

    ByLee Keybum

    I don’t get hacked. I get audited.

    AdaptHealth says it “contained” the breach, which is adorable—like telling me the house fire is under control because the office paperwork is still on the desk. Their disclosure also points to the real culprit: attackers exfiltrated a stored “password file” tied to insurance-billing systems. That’s not just “data” in the abstract. That’s the credential plumbing that makes patient portals and billing workflows actually work—right up until it doesn’t.

    The company’s version of events is basically: an approach involving social engineering aimed at a third-party contractor session, followed by containment steps so AdaptHealth can keep servicing patients. But the contradiction audit is still doing laps: they say the incident is contained, yet they also confirm stolen insurance-billing passwords plus related personal information (and categories that may include sensitive health-related information). And they also say full scope/impact details aren’t determined yet—so the only outcome we can count on with certainty is the one users already recognize.

    Reset loops. Identity checks. Another “please verify” email that pops up like it’s subscription-based. Because when the password machinery gets taken, you don’t just lose access—you inherit the administrative chore list. PR math says “contained!” Patient math says “cool, so which portal do I have to reset again?”

    AdaptHealth’s contained narrative may be good for operations. But for ordinary people, “contained” still lands like this: the same system that helps you handle coverage and payments has been turned into a recurring “prove you’re you” obstacle course—twice, because apparently the bill always comes due.

  • |

    Tiny Tweak, New Monopoly: Evergreening Shouldn’t Mean a Bigger Bill

    ByJustin Jest

    I’m not saying the billion-dollar backroom worships a stopwatch, but the patent expires and—boom—“innovation” shows up as an extended-release, a new coating, or a combo pill. Same original drug, new paperwork, new dose, with that fresh little seal slapped on like it’s a brand-new invention. Not every reformulation is a real breakthrough; sometimes it’s just the legal version of swapping a street sign and calling it “progress.”

    When competition waits, Medicare keeps paying while the price clock does a victory lap under a new nameplate. A small change shouldn’t mean a bigger bill—yet the system treats “tiny tweak” like it’s the next chapter in monopoly fanfic, just with higher invoices.

  • |

    Follow the Money: When Medical Bills Wipe Out a Paycheck, the System Is Broken

    ByPhil McCracken

    I’m Phil McCracken, and I can tell when “care” turns into an accounts-receivable treadmill: getting sick shouldn’t mean going broke, yet premiums and deductibles keep showing up, then the Insurance Explanation of Benefits arrives like it’s done—until “another bill, another worry” turns into a collections-department vibe. One hospital bill later—$18,732.61, past due—and the paycheck is doing parkour instead of paying rent.

    That’s the contradiction the brochure won’t admit: “even insured” doesn’t mean protected, it means paperwork choreography—right up to the moment a medical bill can wipe out a paycheck and the whole system feels broken. So yeah, follow the money: who profits from making health care feel like a financial trap, instead of health care that should heal people, not bankrupt them.

  • |

    Windstone Medical Just Got a Real FDA “Correction”… Which Is Exactly the Word the Scammers Love

    ByHolden McGroin

    My phone buzzed like it just discovered freedom: “FDA recall correction.” Then my brain, still wearing its algorithm trench coat, went full panic boutique and started shopping for a refund like it’s a limited-edition disaster. But the actual anchor here is way less dramatic and way more boring: the FDA posted an updated “Convenience Kit Correction” communication for Windstone Medical Packaging on July 6, 2026, and described the issue as a Class I recall in that official notice. Translation: this is safety paperwork, not a payout announcement, not an app update, and definitely not your cue to click the first “refund” button you see.

    Here’s the contradiction the scammers rely on: the words that mean “protection” in an FDA document are basically catnip for smishing/text scams. The pattern the FTC has warned about is scammers texting that an item was recalled and offering a refund—if you click a link to “claim” or “update.” In other words, “correction/recall” gets used like a forged passport: same format, different country. One path is consumer safety. The other path is click-harvested “customer support.”

    And who benefits from the confusion? The people who turn safety vocabulary into a monetization funnel. Real FDA classifications exist to push you toward the right handling steps. Scam messages exist to push you toward one thing consistently: skipping your verification process. The panic machine doesn’t need your health to be at risk—just your urgency, your inbox trust, and that split-second where you think, “Sure, this sounds official.”

    So here’s your group-chat emergency subscription smell test: if a text promises money, uses urgent recall wording, and asks you to click to verify or claim, treat it like bait unless you can confirm the details through trusted, official channels. The FDA correction is the paperwork. The panic post is the product being sold to you.

End of content

End of content